BBR Partners LLC Sells 1,298 Shares of Pfizer Inc. (NYSE:PFE)

BBR Partners LLC reduced its stake in shares of Pfizer Inc. (NYSE:PFE) by 3.0% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 42,024 shares of the biopharmaceutical company’s stock after selling 1,298 shares during the quarter. BBR Partners LLC’s holdings in Pfizer were worth $1,176,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Olistico Wealth LLC acquired a new stake in shares of Pfizer in the 2nd quarter valued at $25,000. MFA Wealth Advisors LLC bought a new position in Pfizer in the second quarter valued at about $29,000. Creekmur Asset Management LLC acquired a new stake in Pfizer in the fourth quarter worth about $32,000. Trivant Custom Portfolio Group LLC raised its holdings in Pfizer by 100.0% during the 1st quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 600 shares during the last quarter. Finally, Financial Connections Group Inc. acquired a new position in Pfizer during the 2nd quarter valued at about $34,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Trading Up 0.4 %

NYSE:PFE opened at $28.51 on Friday. The company has a market cap of $161.55 billion, a P/E ratio of -475.09, a price-to-earnings-growth ratio of 1.02 and a beta of 0.68. Pfizer Inc. has a twelve month low of $25.20 and a twelve month high of $35.28. The business has a 50 day moving average price of $29.05 and a two-hundred day moving average price of $28.04. The company has a quick ratio of 0.60, a current ratio of 0.86 and a debt-to-equity ratio of 0.65.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, July 30th. The biopharmaceutical company reported $0.60 EPS for the quarter, topping analysts’ consensus estimates of $0.46 by $0.14. The company had revenue of $13.28 billion during the quarter, compared to the consensus estimate of $12.96 billion. Pfizer had a negative net margin of 4.66% and a positive return on equity of 8.42%. The company’s quarterly revenue was up 2.1% on a year-over-year basis. During the same period in the prior year, the business posted $0.67 EPS. As a group, analysts expect that Pfizer Inc. will post 2.66 EPS for the current fiscal year.

Pfizer Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Tuesday, September 3rd. Shareholders of record on Friday, July 26th were paid a $0.42 dividend. This represents a $1.68 dividend on an annualized basis and a yield of 5.89%. The ex-dividend date of this dividend was Friday, July 26th. Pfizer’s dividend payout ratio is currently -2,799.53%.

Analyst Upgrades and Downgrades

PFE has been the subject of a number of recent research reports. StockNews.com raised shares of Pfizer from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. UBS Group upped their target price on shares of Pfizer from $30.00 to $31.00 and gave the company a “neutral” rating in a research report on Wednesday, July 31st. Wells Fargo & Company raised their price target on Pfizer from $28.00 to $30.00 and gave the stock an “equal weight” rating in a research report on Wednesday, July 31st. Barclays increased their target price on Pfizer from $30.00 to $32.00 and gave the company an “equal weight” rating in a research note on Wednesday, July 31st. Finally, Daiwa America upgraded Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research report on Wednesday, August 7th. Eight research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $34.54.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.